Innovent Biologics and Pfizer sign global licensing deal covering 12 oncology drug candidates
May 29, 2026 | 14:58
Innovent Biologics and Pfizer have entered a strategic global licensing and collaboration agreement covering the research and development of 12 promising oncology drug candidates, combining Innovent's pipeline with Pfizer's global development and commercialisation capabilities.
Mobile Version